Evidence map›Paper›PMID 42350615›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2026

Genotype-dependent [

Paul Dahlmann, Maria Geuss, Matthias Auer, Ulrike Disko, Katharina Wang, Nabeel Mansour, Christine Schmid-Tannwald, Svenja Nölting, Nicole Reisch, Martin Reincke and 4 more

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Paul DahlmannDepartment of Nuclear Medicine, LMU University Hospital, LMU Munich, 81377, Munich, Germany.
Maria GeussDepartment of Nuclear Medicine, LMU University Hospital, LMU Munich, 81377, Munich, Germany.
Matthias AuerDepartment of Medicine IV, Endocrinology, Diabetes and Metabolism, LMU University Hospital, LMU Munich, Ziemssenstr. 5, 80336, Munich, Germany.
Ulrike DiskoDepartment of Medicine IV, Endocrinology, Diabetes and Metabolism, LMU University Hospital, LMU Munich, Ziemssenstr. 5, 80336, Munich, Germany.
Katharina WangDepartment of Medicine IV, Endocrinology, Diabetes and Metabolism, LMU University Hospital, LMU Munich, Ziemssenstr. 5, 80336, Munich, Germany.
Nabeel MansourDepartment of Radiology, LMU University Hospital, LMU Munich, 81377, Munich, Germany.
Christine Schmid-TannwaldDepartment of Radiology, LMU University Hospital, LMU Munich, 81377, Munich, Germany.
Svenja NöltingDepartment of Medicine IV, Endocrinology, Diabetes and Metabolism, LMU University Hospital, LMU Munich, Ziemssenstr. 5, 80336, Munich, Germany.
Nicole ReischDepartment of Medicine IV, Endocrinology, Diabetes and Metabolism, LMU University Hospital, LMU Munich, Ziemssenstr. 5, 80336, Munich, Germany.
Martin ReinckeDepartment of Medicine IV, Endocrinology, Diabetes and Metabolism, LMU University Hospital, LMU Munich, Ziemssenstr. 5, 80336, Munich, Germany.
Christian LottspeichDepartment of Medicine IV, Endocrinology, Diabetes and Metabolism, LMU University Hospital, LMU Munich, Ziemssenstr. 5, 80336, Munich, Germany.
Matthias KroissDepartment of Medicine IV, Endocrinology, Diabetes and Metabolism, LMU University Hospital, LMU Munich, Ziemssenstr. 5, 80336, Munich, Germany.
Rudolf A WernerDepartment of Nuclear Medicine, LMU University Hospital, LMU Munich, 81377, Munich, Germany.
Friederike VölterDepartment of Nuclear Medicine, LMU University Hospital, LMU Munich, 81377, Munich, Germany. friederike.voelter@med.uni-muenchen.de.ORCID http://orcid.org/0000-0001-6157-0363

Funding

Deutsche Forschungsgemeinschaft RE752/30-1, 314061271-TRR 205Else Kröner-Fresenius-Stiftung 2012_A103, 2015_A228
6 · The paper itself

Abstract

introduction[

methodsConsecutive PPGL patients with [

results69 patients presenting with 86 tumour lesions were analyzed. Patient-based sensitivity was 97.1% (67/69; 95%-CI 89.9-99.7) and lesion-based sensitivity 94.2% (81/86; 95%-CI 87.0-98.1%). Lesion-based sensitivity was 96.3% in non-metastatic disease (77/80; 95%-CI 89.4-99.2%) and 66.7% in metastatic disease [4/6; 95%-CI 22.3-95.7%]). Quantitative analysis showed a high image contrast (median TBR: 6.9). Cluster 2 showed less uptake intensity than sporadic, cluster 1a and cluster 1b tumours (TBR/SUV

conclusion[

Indexed as

Adrenal Gland NeoplasmsDihydroxyphenylalanineGenotypeParagangliomaPheochromocytomaPositron Emission Tomography Computed TomographyAdultAgedBiological TransportCohort StudiesFemaleHumansMaleMiddle AgedDihydroxyphenylalaninefluorodopa F 18[18F]FDOPAGenetic clusterGenotypeMolecular imagingParagangliomaPET/CTPheochromocytoma

Identifiers

PMID42350615

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.